Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Antifungal Drugs market size was estimated at USD 14.9 billion in 2021 and is expected to surpass around USD 20.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 3.9% during the forecast period 2022 to 2030.

Key Takeaways:

• By Drug Class, the U.S. Antifungal Drugs market was valued at USD 5.7 Billion in 2021 and expected to witness growth at a CAGR of 2.9% from 2022 to 2030.
• Several types of fungicidal preparations, such as creams, sprays, tablets, and injections, are available. Increasing adoption of these products is anticipated to drive the market during the forecast period
• The echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks
• The candidiasis indication segment is expected to witness the fastest CAGR over the forecast period due to increasing drug resistance of the Candida species to Azoles
• North America held the largest market share in 2021 owing to higher awareness levels pertaining to the treatment of fungal infection and the presence of a large target population
• In Asia pacific, the market is projected to register the fastest growth during the forecast period due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases among the population
• Companies are focusing on the development of effective therapeutic agents for the treatment of systemic fungal infections in immune-compromised patients
• Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics are poised to provide the market with lucrative growth opportunities. For instance, Astellas Pharma partnered with Vical Incorporated for the development of VL-2397, an antifungal drug for the treatment of pulmonary aspergillus

The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market. Fungal infections encompass both systemic and superficial infections including infections of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents. Moreover, mounting cases of patients suffering from hospital-acquired or nosocomial infections and infectious diseases are poised to propel the growth of the market during the forecast period.

 The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Report Scope of the Antifungal Drugs Market

Drug Class Insights

The Azoles drug class segment dominated the market for antifungal drugs and accounted for a revenue share of 47.6% in 2021 with leading therapeutic agents such as Noxafil, Vfend, Diflucan, and Cresemba. The dominance of the market can be attributed to broad-spectrum activity delivered by Azoles. These agents support fungistatic activities by inhibiting fungal enzymes. Azoles are used in the treatment of candidemia, blastomycosis, systemic candidiasis, and ocular fungal infections. Azoles are also used in the treatment of systemic fungal infections, classified into triazoles and imidazoles. They offer a wide spectrum of activity and enhanced safety levels. Triazoles have fewer adverse effects, less serious drug interactions, and improved absorption and distribution properties. The aforementioned benefits of the use of azoles are contributing to the growth of the segment.

Increasing drug resistance among Aspergillus and Candida species, specifically to azoles, is expected to restrict the growth of the market for antifungal drugs. Allylamines are synthetic fungicidal agents that are anticipated to register a CAGR of over 2.2% during the forecast period. These drugs are prescribed for nail infections, jock itch, athlete foot, and ringworms. Lamisil is the most commonly prescribed topical antifungal medication after fluconazole for the treatment of systematic antifungals by dermatologists. Thus, the rising prevalence of dermatological diseases is likely to further boost the growth of the segment.

Indication Insights

Candidiasis, which is the most commonly occurring systemic fungal infection, is expected to exhibit the fastest CAGR over the forecast period. It is a yeast infection caused by genus Candida. Its treatment has evolved over time. Some of the changes include appropriate usage of echinocandins and broad-spectrum azoles for treatment of candidemia, mucosal candidiasis, and invasive candidiasis. Increasing number of patients, who are more susceptible to fungal infections, is a key driver for the segment. In addition, growing awareness among patients and healthcare professionals is poised to spur the growth of the antifungal drugs market.

The dermatophytosis segment is anticipated to hold a sizeable share in the market during the forecast period due to the rising incidence of skin infections in children. In the recent decade, the incidence of this infection has considerably increased due to an unhealthy lifestyle. This has raised concerns for immunocompromised patients, who are susceptible to extensive lesions and atypical manifestations due to fungi.

The others segment of indications includes invasive pulmonary aspergillosis, rhinocerebral mucormycosis, and endocarditis. The availability of a limited number of therapeutics for the treatment of invasive fungal infections as compared to bacterial infections is one of the major problems faced by clinicians. Only a few classes of drug molecules have been developed over the past 30 years. Players are focusing on the development of effective therapeutic agents for the treatment of systemic fungal infections in immunocompromised patients. Various public-private partnership agreements for the development of novel therapeutics are projected to provide the market with tremendous growth opportunities.

Regional Insights

North America dominated the market for antifungal drugs and accounted for a revenue share of 41.5% in 2021. The growth of the region can be attributed to the increasing incidence of infectious diseases. Rise in prevalence has raised clinical urgency to increase the usage of these drugs and has boosted the development of innovative drugs with fast-track approvals by the FDA. In addition, the presence of established pharmaceutical companies, which are consistently striving for extensive commercialization of their drugs and enhancing their geographical reach, is anticipated to be a key factor escalating the growth of the regional market.

In the Asia Pacific, the market for antifungal drugs is estimated to exhibit the highest CAGR during the forecast period. The presence of a huge base of target population, growing disposable income and availability of drugs, and high unmet clinical needs are contributing to the growth of the regional market. Thus, global players are focusing on high R&D investment as well as commercializing branded drugs at a relatively lower price in the region. Japan held a substantial share in the APAC market in 2021, owing to an increasing medical expenditure and greater insurance coverage.

Some of the prominent players in the Antifungal Drugs Market include:

• Novartis AG
• Pfizer, Inc.
• Bayer AG
• Sanofi
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Abbott
• Glenmark
• Enzon Pharmaceuticals, Inc.
• Astellas Pharma, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antifungal Drugs market

• Drug Class
• Azoles

• Voriconazole (Vfend)
• Posaconazole (Noxafil)
• Clotrimazole (Canesten)
• Isavuconazole (CRESEMBA)
• Others
• Echinocandins
• Caspofungin (Cancidas)
• Micafungin (Mycamine/ Funguard)
• Others
• Polyenes
• Amphotericin (AmBisome)
• Others
• Allylamines
• Terbinafine (Lamisil)
• Others
• Others
• Indication
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Invasive Candidiasis
• Vulvovaginal Candidiasis (VVC)
• Mouth/Throat/Esophageal Candidiasis
• Other Candida Infections
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Antifungal Drugs Market Study:

• Growth of Antifungal Drugs in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Antifungal Drugs and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Antifungal Drugs Consumption Analysis
•  Antifungal Drugs Production Analysis
•  Antifungal Drugs and Management